Toll-like receptor 7–Myeloid differentiation primary response 88–TNF receptor-associated factor 6 signaling axis (TLR7–MyD88–TRAF6)

The TLR7–MyD88–TRAF6 signaling axis is a critical component of the innate immune system, primarily responsible for detecting single-stranded RNA (ssRNA) from viruses and endogenous sources (NIH, 2019; Spandidos Publications, 2018). Upon activation of the endosomal Toll-like receptor 7 (TLR7), the adapter protein MyD88 is recruited, which then facilitates the activation of TRAF6 and subsequent downstream signaling through NF-kappaB and IRF7 (Reactome; NIH, 2020). This cascade leads to the robust production of type I interferons and proinflammatory cytokines, which are essential for antiviral defense but can also drive autoimmune pathology if dysregulated (NIH, 2023; NIH, 2020). In therapeutic contexts, TLR7 agonists are used to enhance immune responses against viral infections and certain cancers, while antagonists and inhibitors of the MyD88-TRAF6 complex are being developed to treat chronic inflammatory and autoimmune conditions like systemic lupus erythematosus (NIH, 2025; NIH, 2024). The pathway is also implicated in the pathogenesis of adult-onset Still's disease and psoriasis, where excessive signaling leads to tissue damage (NIH, 2023; Frontiers, 2024). Targeting this axis requires careful modulation to avoid systemic inflammatory responses or excessive immunosuppression (NIH, 2025; ResearchGate, 2026).

Other names

TLR7-MyD88-TRAF6 pathwayTLR7-MyD88-TRAF6 axisTLR7-dependent MyD88 signalingTLR7-MyD88-TRAF6-NF-kappaB signaling

Modulation of the signaling cascade through agonism or antagonism of the TLR7 receptor or inhibition of the MyD88 and TRAF6 adapter proteins to regulate the production of type I interferons and proinflammatory cytokines.